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Abstract
Systemic lupus erythematosous (SLE) is an autoimmune disease with an important clinical and biological heterogeneity. B
lymphocytes appear central to the development of SLE which is characterized by the production of a large variety of
autoantibodies and hypergammaglobulinemia. In mice, immature B cells from spontaneous lupus prone animals are able to
produce autoantibodies when transferred into immunodeficient mice, strongly suggesting the existence of intrinsic B cell
defects during lupus. In order to approach these defects in humans, we compared the peripheral B cell transcriptomas of
quiescent lupus patients to normal B cell transcriptomas. When the statistical analysis is performed on the entire group of
patients, the differences between patients and controls appear quite weak with only 14 mRNA genes having a false
discovery rate ranging between 11 and 17%, with 6 underexpressed genes (PMEPA1, TLR10, TRAF3IP2, LDOC1L, CD1C and
EGR1). However, unforced hierarchical clustering of the microarrays reveals a subgroup of lupus patients distinct from both
the controls and the other lupus patients. This subgroup has no detectable clinical or immunological phenotypic peculiarity
compared to the other patients, but is characterized by 1/an IL-4 signature and 2/the abnormal expression of a large set of
genes with an extremely low false discovery rate, mainly pointing to the biological function of the endoplasmic reticulum,
and more precisely to genes implicated in the Unfolded Protein Response, suggesting that B cells entered an incomplete
BLIMP1 dependent plasmacytic differentiation which was undetectable by immunophenotyping. Thus, this microarray
analysis of B cells during quiescent lupus suggests that, despite a similar lupus phenotype, different biological roads can
lead to human lupus.
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Introduction
Systemic lupus erythematosous (SLE) is an autoimmune disease
which is clinically and biologically characterized by a wide
spectrum of signs variable from one patient to another. Indeed, the
diagnosis of SLE mainly relies on the association of clinical and
biological symptoms, some of which being validated as diagnostic
criteria [1]. Not only different organs can be affected in groups of
patients with SLE, but also the immunological hallmark of the
disease, the autoantibodies, are diversely expressed with the
exception of antinuclear antibodies which are quasi-constant in
patients. This phenotypic heterogeneity of SLE patients may
reflect different genetic contributions (i.e. various combinations of
susceptibility genes) and/or different environmental factors which
could lead to diverse immunopathological consequences. Among
the many immune cell types which have been implicated in this
heterogeneous disease, B lymphocytes appear central to the
development of lupus and deserve further attention because: 1/
they produce the autoantibodies, 2/they are activated during the
disease, 3/they are responsible for the frequent hypergammaglob-
ulinemia, and 4/they could present some intrinsic defects
responsible for lupus traits and currently unknown. Indeed, in
the spontaneous lupus prone mice NZB/W F1, it was shown that
immature B cells from the parental lines NZB and NZW, when
transferred to immunodeficient mice, produced hypergammaglob-
ulinemia and antiDNA antibodies [2]. In the recent years, the B
cell phenotype was extensively studied during lupus leading to the
dissection of quantitative abnormalities of B cell subpopulations
like naı ¨ve B cells, CD5 B cells, transitional B cells, memory and
plasma B cells based on the expression of various membrane
markers [3–8]. Some of these B cell abnormalities correlate with
lupus activity and could reflect the extrinsic influence of various
factors, like type I Interferons and/or BAFF, on the B cell
subpopulations [9–11]. In an effort to track down putative intrinsic
B cell defects during SLE, we analysed the transcriptomas of
purifed B cells from inactive patients without immunosuppressive
treatment, and compared the SLE B cell gene expression to
healthy individual B cell transcriptomas. This approach, using
purifed B lymphocytes instead of a mixture of peripheral
mononuclear cells and non hypothesis driven large scale micro-
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biological pathways, and to define such intrinsic B cell defects. The
overall statistical analysis of the differential gene expression (17
patients versus 9 controls) identified a very low number of genes
with an acceptably low false discovery rate (FDR) showing that
gene expressions were quite similar between quiescent lupus B cells
and controls. However, a subgroup of patients was clearly distinct
from the others and from the controls, with differentially expressed
genes mainly implicated in plasmacytic differentiation and
confirming at the B cell level the heterogeneity of the pathways
leading to lupus.
Materials and Methods
Patients
17 patients (15 females and 2 males) with the diagnosis of SLE
were selected for this study after they gave their informed consent.
The SLE diagnosis was based on the presence of at least 4 criterias
among those defined by the American College of Rheumatology.
The lupus was inactive in these patients for more than 6 months,
with a Systemic Lupus Erythematosous Disease Activity Index
(SLEDAI) score less than 4 [12], and they did not receive any
immunosuppressive drug. If they needed steroids, the patients
were not treated with more than 10 mg of prednisone per day (4
patients). 10 patients were treated with hydroxychoroquine. The
clinical characteristics of the patients are presented in Table 1.
The 10 control subjects were healthy individuals, (8 females and 2
males) ageing from 23 to 53 years, with no personal nor familial
history of autoimmune disease. 17 patients (15 females and 2
males) with the diagnosis of SLE were selected for this study after
they gave their written informed consent. This study was approved
by the ethic comity of the Ho ˆpitaux Universitaires de Strasbourg.
B lymphocyte preparation and RNA purification
Peripheral blood was drawn into heparin-containing sterile tubes
and peripheral blood mononuclear cells were prepared by Ficoll
(Amersham) density gradient centrifugation for immediate use. B
cells were labeled with a biotin anti-CD19 monoclonal antibody
(HIB19 clone, Pharmingen) at 4uC and revealed by phycoerythrin-
labelled streptavidin (Biomeda) before immediate B cell sorting with
high speed cell sorter (FACS Diva, Beckton-Dickinson). Total
RNAs from the sorted B cells were extracted using TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions. They
were then precipitated in Glycogen (Invitrogen) and suspended in
DNAase-free and RNAase-free water (Gibco). The quality of the
RNA preparations was always checked with RNAlabChip (Agilent)
before any further step. Good quality RNA preparations (approx-
imately 50 ng per preparation) were amplified using the Affymetrix
2 cyclecDNAsynthesiskit.Inordertoreducethevariabilityofthese
preparations, one control B cells and generally 2 patients’ B cells
preparations were treated simultaneously.
Gene micro arrays preparations and GeneChip analysis
cRNAs were synthesized, biotin-labelled and hybridized to the
AffymetrixGeneChiphumangenomeU133plus2.0(withprobesets
representing 38,572 UniGene clusters) according to the manufac-
turer’s instructions. After hybridization and washings, arrays were
stained with PE-conjugated streptavidin(10 mg/ml) before scanning.
Raw Affymetrix data (available at http://www.ncbi.nlm.nih.gov/
projects/geo/query/acc.cgi?acc=GSE30153) were analyzed using
R (R Development Core Team, 2008; The Comprehensive R
Archive Network: http://cran.r-project.org/) and Bioconductor
(Bioconductor: http://www.bioconductor.org/) softwares [13].
The quality of the 27 Affymetrix genechips and RNA was assessed
using the Bioconductor AffyPLM and simpleaffy packages, with qc,
Table 1. Clinical features, and disease activity index at the time of the study.
Patient n6 Age Sex
Duration of
disease (years) SLEDAI
IgG levels
(g/l)
ANAs
title Anti-dsDNA Steroids Chloroquine
1 36 F 3 0 8.49 1/160 22 2
2 59 F 20 3 8.15 1/1280 + 2 +
3 38 F 18 0 8.29 1/1280 22 +
4 37 F 9 2 7.3 1/640 ++ +
5 36 F 8 4 7.22 1/1280 + 22
6 36 F 9 0 10.2 1/160 22 2
7 41 M 9 0 11.2 1/640 22 2
8 55 F 15 4 13.8 1/320 22 2
9 47 F 9 0 15.9 1/320 22 2
10 36 F 12 4 7.68 1/1280 + 22
11 37 F 8 2 9.47 1/1280 ++ +
12 53 F 19 0 9.76 1/1280 2 ++
13 30 F 2 0 7.8 1/160 22 +
14 41 F 7 0 11.9 1/1280 2 ++
15 23 M 8 4 7.3 1/640 + 2 +
16 37 F 18 4 8.07 1/1280 + 2 +
17 50 F 26 0 10.5 1/640 22 +
Disease and treatment were stable for at least 6 months. SLEDAI: Systemic Lupus erythematosus disease activity index; IgG normal range: 7–14 g/l, ANA: antinuclear
antibodies.
doi:10.1371/journal.pone.0023900.t001
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control chip showing too many defects was left aside, thus further
analysis were carried out on 9 control and 17 patient chips. For
normalization and background correction, Raw values were pre-
processed with RMA or GCRMA (library simpleAffy). As further
analysiswithRMAorGCRMAdatagavesimilarresults,onlyresults
with GCRMA expression values will be shown. According to the
histogram distribution of GCRMA expression values (Fig. 1), we
considered as unexpressed genes (both in patients and controls),
genes with expression values below 4. Genes with values lower than
this threshold were eliminated: of the 54,675 Affymetrix probe sets,
only 18,271 (33%) correspond to genes expressed in B lymphocytes.
Identification of differentially expressed genes and estimation of the
False Discovery Rate (FDR, [14,15]) were carried out using the
Significance Analysis of Microarrays (SAM) algorithm available in
the siggenes package [16].
Data clustering
The dist and hclust functions of the simpleaffy library were used
to build hierarchical clusterings of the data.
QRT-PCR Analysis
cDNAs from total RNAs were prepared after patients and
control B cell separations using the high capacity cDNA Reverse
transcription Kit (Applied Biosystems). 10 ng of each cDNA was
subjected to QRT-PCR using Applied Biosystems TaqMan assays
(validated for each selected gene) on the ABI Prism 7000
instrument. The DDCt provided the target gene expression value
by comparison with a calibrator sample (Applied Biosystems). The
patients and control samples and the calibrator were first
normalized by the relative expression of the 18s.
B Lymphocyte ligands and lupus
Zhu et al. in 2004 published an extensive analysis of mouse
splenic B cell gene expression changes in response to in vitro
stimulation with 33 ligands of B lymphocytes [[17], and Data
available online: UCSD-Nature Signaling Gateway, Alliance for
Cellular Signaling, AfCS Data Center, B-cell ligand screen,
http://www.signaling-gateway.org/data/cgi-bin/table.cgi?cellabbr
=BC]. In an attempt to find associations between human SLE and
theseligands, we compared patterns ofgenes differentially expressed
in B lymphocytes during SLE (our results in the subgroup of 5
patients) and in response to these ligands (Zhu’s results). In order to
identify homolog human and mouse genes, i.e gene with the same
symbol name, clone identifiers are converted to gene symbol names.
For Affymetrix probe sets the conversion to gene symbols is
straightforward using the Affymetrix NetAffx Analysis Center
(http://www.affymetrix.com/analysis/index.affx). In contrast the
conversion of mouse clone ID to symbol names require queries to
several data bases as the custom Agilent cDNA Microarray chip
used in Zhu et al. publication was made up of clones from four
libraries: RIKEN, NIA, Research Genetics, and Genome system-
s.The Representing Factor (http://www.nemates.com/uky/MA/
progs/overlap_stats.html) and the Resampling statistical methods
[18], and available online: http://www.resample.com/content/
text/index.shtml] were used to compare the patterns of genes
differentially expressed in human and mouse B lymphocytes.
The identification of the biological pathways and of the ontology
groups (biological processes and molecular functions) of selected
list of genes differentially expressed in the 5 lupus patients subgroup
was performed using the DAVID program with a Bonferroni
correction for multiple testing (DAVID Bioinformatic Resources,
NIAID, NIH), and the CYTOSCAPE program with the MiMI
plugin [19].
Results
The patients’ characteristics are presented in Table 1. They
were all considered of having an inactive phase of SLE with a
variable disease duration (2 to 26 years). B cell purity was checked
by FACS analysis of sorted CD19 positive cells ( more than 96%).
Figure 1. Histogram distribution of GCRMA expressions values. Genes with expression values below 4 were considered unexpressed in B
cells both in patients (A) and in control (B).
doi:10.1371/journal.pone.0023900.g001
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to normal B cells
According to the MIAME recommendations, the data discussed
in this publication have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO Series
accession number GSE30153 (http://www.ncbi.nlm.nih.gov/
projects/geo/query/acc.cgi?acc=GSE30153) as well as the full
normalized and annotated results of the RMA analysis of the
2,327 genes with initial p values of less than 0.05 (Table S1). Then,
the B cells transcriptional profiles originating from the 17 lupus
patients compared to the 9 normal individuals were analysed using
the SAM algorithm and multiple testing correction according to
Benjamini et al [14,15]. Using this stringent statistical analysis, and
after removing the upregulated Ig genes from this short list, it
appears that only a very small number of genes (14 out of the
18,271 which were expressed in B cells) are differentially expressed
with a FDR ranging from 11 to 17% (Table 2). At first glance,
these results indicate that, at the transcriptomal level, and during
the inactive phases of the disease, lupus B cells are very similar to
normal B cells. The differentially expressed genes were checked by
real time qPCR only in a few patients (because of the availability of
the cDNAs) and were confirmed to be up or downregulated during
lupus. Among these genes, it is interesting to note that TRAF3IP2
(alias ACT1) is a negative regulator of B cell function, its absence
leading to lymphoproliferation and autoantibody production [20],
but ACT1 is also essential in IL-17 dependent signaling during
autoimmune diseases [21], IL-17 being implicated during lupus
physiopathology [22]. On the other hand, the low level of
expression of CD1c mRNA could be related to the fact that CD1c
is highly expressed on unswitched memory B cells or circulating
counterpart of marginal zone B cells [23], this subpopulation being
decreased during the inactive phase of lupus [24]. TLR10 has to
date no defined agonist or function but is apparently functional
with a distinct signaling pathway in B cells [25,26].
A subset of SLE patients have a distinct gene expression
profile
Unforced hierarchical clustering of the patients and the controls
was performed with the 18,271 genes expressed in the B cells. The
figure 2A shows that the gene expressions of the patients and the
controls were quite similar, confirming the previous statistical
analysis. However, the same unforced hierarchical clustering
identifies a subgroup of 5 patients with a distinct gene expression
profile. The statistical analysis comparing the gene expression of
these 5 patients with the controls and the other patients was indeed
highly significant. Extremely low FDRs (less than 0.01) were
associated with the differential expression of approximately 800
genes (Table S2, and Heat-map of the first 50 genes in Fig. 2B).
Considering the availability of the mRNAs (which was the limiting
factor), we only checked by real time qPCR the expression levels of
6 selected genes in 2 patients and one control (ADA, RRM2,
CAV1, XBP1, ARHGAP24, FKBP11) and confirmed the
microarray results (Fig. 3). Looking for the origin of this peculiar
gene expression profiles in these 5 patients, we first tried to find
differences in the clinical phenotype of the patients but we were
unable to find such differences (gender, age of onset, disease
duration, activity score, levels of serum Ig and anti nuclear
antibodies, treatments at the time of sampling). Second, since the
difference could originate from a distinct representation of the B
cell subpopulations in these 5 patients, we checked the detailed
cytofluorometric patterns (CD19, IgG, IgM, IgD, CD138, CD27,
CD86) observed on B cells from both controls and patients.
Differences were evidenced between the patient and the control
groups [24], but we did not see any statistical difference between
Table 2. Genes over or underexpressed in lupus patients B cells (FDR from 11 to 17%) compared to control B cells.
Probes
Xfold
(log2) Unigene Gene symbol
Function
(NCBI)
1554474_a_a
209708_at
1.93 Hs.6909 MOXD1 Catecholamine metabolism
201890_at
209773_s_at
4.44 Hs.226390 RRM2 Oxidoreductase activity, implicated in DNA replication
202589_at
1554696_s_at
3.79 Hs.592338 TYMS DNA replication and repair
201543_s_at
210790_s_at
1.97 Hs.499960 SAR1A GTPase activity, intracellular protein transport
228486_at
228485_s_at
2.32 Hs.573495 SLC44A1 Transmembrane transport
201923_at 1.98 Hs.83383 PRDX4 Antioxidant enzyme, regulatory role in the NF-kappaB
pathway
203857_s_at 2.63 Hs.477352 PDIA5 Isomerase activity, protein folding
39249_at 1.40 Hs.234642 AQP3 Glycerol and water channel activity
222450_at 0.49 Hs.517155 PMEPA1 Androgen receptor signalling pathway
215411_s_at 0.71 Hs.654708 TRAF3IP2 Positive regulation of I-kappaB kinase/NF-kappaB cascade
223751_x_at 0.67 Hs.120551 TLR10 Innate immunity Potential Pam(3)CSK(4) receptor
205987_at 0.42 Hs.132448 CD1c Presentation of primarily lipid/glycolipid antigens
223228_at 0.66 Hs.715637 LDOC1L Unknown
227404_s_at
201694_s_at
0.38 Hs.326035 EGR1 Transcriptional regulator
doi:10.1371/journal.pone.0023900.t002
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CD19/CD138 double positive cells, CD19/CD27 double positive
cells, and CD19/CD86 double positive cells were found. Third,
the differential gene expression could originate from B cell
extrinsic or intrinsic properties pointing to original biological
pathways in these 5 patients.
Ligand signature?
Still focusing on the differential gene expression between the
subgroup of patients and the controls, the results could represent
intrinsic or extrinsic gene expression abnormalities or both. In
order to approach the possible influence of extrinsic factors, we
took advantage of the Signaling gateway data center which gives
the results of an extensive analysis of microarrays performed on
murine purified splenic B cells during in vitro stimulation with 33
different ligands [17]. Thus, we compared our list of in vivo
differentially expressed human genes during SLE with differen-
tially expressed murine genes under influence of these ligands. To
be precise, we specifically compared the differentially expressed
(1.5 fold change) murine genes after 4 h ligand stimulations with
our list of highly differentially expressed genes originating from the
subgroup of the 5 SLE patients( thereby named SLE list). Different
Figure 2. A subgroup of 5 patients stands out from the others. (A) Dendrogram obtained by unforced hierarchical clustering of the
microarrays from the 17 patients and the 9 controls. A subgroup of 5 patients (surrounded by a dashed line) stands out from the others. (B) Heat-map
of the 50 first differentially expressed genes in these 5 patients compared to controls after filtering the results for low signal. Over-expressed genes
are shown in red and under-expressed are depicted in green.
doi:10.1371/journal.pone.0023900.g002
Figure 3. Quantitative RT-PCR of 6 selected genes in 2 patients and one control. FKBP11, RRM2, XBP1, ADA, CAV1 and ARHGAP24
expressions were determined by real time quantitative RT-PCR. Each sample was normalized to the endogenous control 18S.
doi:10.1371/journal.pone.0023900.g003
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murine and human microarrays were considered for this analysis,
2/we identified the different ligand regulated gene files, 3/among
these files, we identified the murine genes which were also present
in the SLE list (common lists of genes) and counted the number of
genes varying in the same direction for each ligand, 4/then, for
each ligand, we calculated the Representing Factor and the
associated probability of finding an overlap set of genes [http://
www.nemates.com/uky/MA/progs/overlap_stats.html]. This cal-
culation leads to identify IL4 imprinting as the only significant
signature in these 5 patients B cells: the common list of genes for
IL4 contained 112 genes with 101 genes varying in the same
direction. This was confirmed by another statistical method
(Resampling, [18]). Type I Interferon (only 35 genes on the
common list, with 30 moving in the same direction), BAFF (33
genes on the common list, with 25 moving in the same direction)
and CD40L (84 genes on the common list, but 59 only varying in
the same direction) did not reach statistical significance.
Biological pathways in the subgroup of 5 patients
In order to analyse the biological significance of differentially
expressed genes in these 5 patients compared to controls, different
tools are available. We used the DAVID program to look for
statistically represented biological pathways. If we enter the SLE
list of genes into the DAVID program, it appears that one
biological pathway is highly significantly overrepresented after a
Bonferroni correction for multiple testing: the endoplasmic
reticulum (p less than 8.8610
211). Among these genes which
point to the endoplasmic reticulum, a large set of genes participate
to the Unfolded Protein Response. Many of these genes are
controlled by the overexpression of BLIMP1, a master regulator of
B cell terminal differentiation: DNAJC3, SEC61A, BIP, SSR4,
PPIB, RPN1… This overexpression of BLIMP1 mRNAs is not
related to EGR1 because the later is also down regulated in these 5
patients [27]. On the other hand, XBP1, whose mRNAs are also
overexpressed, could be inactive since its specific target genes are
not upregulated (SLC30A, ARHQ, OBF1). It is interesting to note
that 1/IL4 is indeed able to induce XBP1, but not the IRE1
activation induced XBP1 splicing which is necessary to produce
the active form of XBP1 [28], and not to induce BLIMP1, and 2/
BI1 mRNAs (Bax Inhibitor 1) are increased in these B cells and
BI1 is known to repress IRE1 activation [29].
At the level of gene interactions, using Cytoscape and the MiMI
program, analysis indicates complex relationships between differ-
entially expressed genes which can belong to distinct biological
pathways. As an example, we can mention the complex network of
possible interactions between FYN, whose mRNAs are down
regulated in these patients, and 8 directly interacting gene
products whose mRNAs are overexpressed in the same cells.
Discussion
Based on two main considerations (the central role of B cells
during SLE, and the possible intrinsic abnormalities of SLE B
cells), we performed the transcriptomic analysis of purified B cells
during non active phases of the disease. Such an analysis 1/should
reduce the variability of the transcriptomas because of the purity of
the analysed cells, and 2/should reduce the risk of focusing on
gene expressions associated with lupus flares and their medical
treatments. The interpretation of the microarrays is here limited to
B cells, avoiding difficulties in data mining linked to heterogeneous
populations of cells present in the peripheral blood mononuclear
cells in unknown proportions [30]. Still the interpretation can be
obscured by the presence of different B cell subpopulations in the
human peripheral blood. Indeed, in a separate set of experiments
starting with the same blood samples, we performed a detailed B
cell immunophenotyping which showed some differences between
control B cells and SLE B cells [24], some of which being
potentially able to explain differentially expressed genes. Despite
these differences, one of the main results of our study is the
important similarity at the transcriptomic level between normal B
cells and SLE B cells during non active phase of the disease. At a
threshold close to 10% for the FDR (upper limit of reasonably
acceptable risk for microarray analysis [31]), only 14 genes out of
18,271 appear differentially expressed. The biological significance
of these differences could be diverse. For instance, the down
expression of CD1c mRNAs could be related to the low
percentage of the CD1c high unswitched memory B cells among
total SLE B cells. On the other hand, the down expression of
ACT1 (TRAF3IP2), could be linked to SLE because of the
importance of this negative regulator on the B cell function [20–
22]. At that stage, it is almost impossible to compare the results of
the different SLE wide genome scans with our microarray results
because of the very limited informations of the functionality of the
different polymorphisms which were described. However, it is
interesting to note that BLK (C8orf13) does not appear on our list
of differentially expressed genes despite the B cell down expression
of this kinase when its regulatory region expresses the ‘‘SLE’’
polymorphism [32]. Whether this polymorphism is present or not
in our patients, or whether the downregulation of BLK only occurs
during an active phase of the disease, remains to be determined.
The second main result of our data is related to the
transcriptomic heterogeneity of the patients. The unforced
hierarchical clustering of the patients and controls revealed a
subgroup of 5 patients with a distinct pattern of mRNA expression
in B cells leading to the identification of a set of genes with a high
statistical significance. Looking for clinical or biological peculiarities
in these 5 patients, we did not find any difference with the other 12
SLE patients. We also compared their B cell subpopulations
patterns, but again did not find any difference. Thus, we are left
with the possibility that the B cell signature of these 5 patients could
be the result of either extrinsic or intrinsic B cell properties.
Lookingforan extrinsicsignature of the SLE B cell transcriptoma
in these five patients, we found a significantly enriched expression of
genes induced by Il4. However, this approach has several limits: 1/
ligand induced gene expression in purified B cells could be different
in mouse and human, although generally speaking these biological
pathways are quite conserved, 2/for comparisons with our human
gene list, we only considered mouse genes that were consistently
modified 4 h after in vitro ligand stimulations, which could ignore
some interesting early and late gene changes, 3/the analysis can be
obscured by the frequent sharing of expression change patterns
between different ligands (anti-Ig, CD40L, BAFF, IL-4, CpG, Type
I Interferons, data not shown). Having in mind these limitations, it
appears that B cells from these 5 inactive SLE patients have only
one weak signature, although we did not find an increase of serum
IL-4 level in these patients (data not shown). However, the serum
level of IL-4, or the IL-4 production by peripheral blood
mononuclear cells during lupus is not clear, with conflicting results
maybe linked to the activation status of the patients [33-36]. It is
interesting to note that the type I interferon signature which was
reported during active SLE was not clearly detected during the
inactive phase of the disease.
To look for intrinsic B cell defects in these 5 patients, we
removed from the list of differentially expressed genes all those that
were shown to be in vitro ligand regulated [17]. Analysis of the
gene product interactions through the Cytoscape program gives
some interesting clues. For instance, the Src family kinase FYN
B Cell Signature during Inactive Systemic Lupus
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almost all the patients, and FYN deficiency in mice induces a
tendency to produce anti-DNA antibodies and proteinuria
through a non immunological mechanism [37]. FYN appears
physically connected to 8 gene products whose mRNAs are
overexpressed in the subgroup of 5 patients (SLAMF1, RICS,
CSF2RB, CAV1, CDK5, CASP3, IL2RB, ATXN1 [38–42]) and
could compete for FYN. The consequences on B cell biology of
such a competition between the possible overexpressed proteins
and the deficient target FYN are currently unknown. Looking for
the origin of low FYN expression in these 5 patients, it is
interesting to note that it is associated with the down expression of
EGR1 which is known to control the FYN gene expression
through an EGR1 binding site located in the promotor region of
FYN [43]. Beside FYN, other genes coding for adhesion molecules
like ICAM and CD44, can be regulated by EGR1 [44,45] their
mRNAs being down regulated in these patients as well.
In order to find activation of biological pathways in the B cells of
these 5 patients, we used the DAVID program. It identifies a large
overrepresented set of genes which are deregulated during the
plasmacytic differentiation of B cells as well as during the Unfolded
Protein Response in different cell types. The fine analysis of the
deregulated genes in these B cells suggests that B cells underwent
Blimp1 induced partial plasmacytic differentiation, but without
further terminal plasma cell differentiation (Fig. 4): BLIMP1 and
XBP1 mRNAs are both overexpressed, but XBP1 could be
inactive because 1/HERPUD1, ADA and ELL2 ( all being target
genes for BLIMP1, but not for XBP1) mRNAs are increased, 2/
On the contrary, specific target genes for XBP1 (SLC30A5,
ARHQ) are not deregulated, which is consistent with an IL-4
influence [28,46]. The precise stimulus that induces BLIMP1 over
expression, but not XBP1 splicing, is not clear but if IL-21 is an
obvious candidate, others are still possible alone or in combina-
tion: BCR, Calcineurin/NFAT, CD40/NFkB [47]. On the other
hand, a new polymorphism associated with SLE was recently
described in the vicinity of the BLIMP1 gene locus, suggesting an
intrinsic property of B cells bearing this variant [48]. Thus, it
seems that, in these patients, B cells are in a stage of intermediate
differentiation, maybe arrested at a step before IRE1 induced
XBP1 unconventional splicing which is necessary to produce the
active form of the protein required for the full plasmacytic
differentiation [49,50]. Consistent with this hypothesis, the serum
levels of IgG were not different in these 5 patients compared to the
12 others, but 20 out of the 32 genes of the plasmablast signature
(module M1.1, [51]) are present in our list.
Such a possible stage opens new questions: 1/is this develop-
mental arrest an intrinsic (constitutive) abnormality of B cells in
these patients, or is it linked to permanent extrinsic stimulation
(IL-4?, IL-21?, Antigen?), 2/do these cells express some new
surface markers which were not detectable during our quite
extensive B cell immunophenotyping? 3/is this stage linked to
lupus susceptibility in these patients, or is it an indication for flare
susceptibility? All these questions will have to be addressed in a
new and large cohort of patients that will be longitudinally tested.
Finally, the description of this subgroup of lupus patients adds
some new insights on the different biological roads which can lead
to a lupus phenotype.
Supporting Information
Table S1 Non normalized data of the 17 patients and 8
controls with probe identification, gene names and
Figure 4. The observed significant variations of mRNAs in the B cells of the five patients are surrended and suggest a BLIMP1
induced partial plasmacytic differentiation.
doi:10.1371/journal.pone.0023900.g004
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Table S2 List of differentially expressed gene with a
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